Key Technology Trends and Selection Considerations for Core Raw Materials for In Vitro Diagnostics in the Bioreagent Industry

The Role and Requirements of Core Raw Materials for In Vitro Diagnostics

The bioreagent industry occupies an upstream position in the in vitro diagnostics (IVD) industry chain, and the performance of core raw materials often determines the sensitivity, specificity, and stability of detection reagents. Common diagnostic raw materials include polymerases for molecular testing, reverse transcriptases, dNTPs, primers and probes, as well as recombinant antigens, monoclonal antibodies, enzyme conjugates, and magnetic beads/microspheres for immunoassays. Compared with general research reagents, diagnostic raw materials need to meet stricter quality requirements, such as lower nuclease residues, higher batch-to-batch consistency, and more comprehensive documentation support. Companies typically introduce the concept of quality by design during the raw material development stage, ensuring product performance by screening expression systems, optimizing purification processes, and establishing critical quality attributes.

In the field of molecular diagnostics, hot-start polymerases, high-fidelity enzymes, and enzyme formulations suitable for lyophilization processes are key industry focuses. Hot-start modification can reduce nonspecific amplification, high-fidelity properties facilitate mutation detection, and glycerol-free or lyophilizable formulations facilitate room-temperature transportation and microfluidic integration. These performance optimizations often involve protein engineering, chemical modification, and screening of lyoprotectants. Different manufacturers may adopt different technical approaches, but all require validation through functional experiments.

Antigen and Antibody Raw Materials: Balancing Specificity and Batch-to-Batch Consistency

The demand for core antigen and antibody raw materials for immunodiagnostic reagents continues to grow. Taking chemiluminescence platforms as an example, antibody affinity, antigen epitope integrity, and enzyme labeling efficiency may all affect detection signals and background. Suppliers in the bioreagent industry typically use recombinant expression, hybridoma screening, or phage display technologies to obtain target proteins. To ensure batch-to-batch consistency, standardization is required in aspects such as cell bank management, culture conditions, purification column efficiency, and storage buffers.

Specificity is the primary indicator for screening antigen and antibody raw materials. Cross-reactivity may cause false positives or false negatives, so companies generally validate using a panel of related proteins or clinical samples. Since this article does not involve specific clinical data, it only emphasizes the necessity of validation from a technical perspective. In addition, antibody stability also requires attention, including activity changes under repeated freeze-thaw cycles and long-term accelerated conditions at 4°C or 37°C. Common specifications may include concentration, purity, buffer composition, shelf life, and recommended storage conditions.

Magnetic Beads/Microspheres and Signal Amplification Materials

Magnetic beads, latex microspheres, fluorescent microspheres, and chemiluminescent substrates are common signal carriers or separation media in immunodiagnostics and molecular diagnostics. The particle size distribution, surface carboxyl density, magnetic response speed, and nonspecific adsorption level of magnetic beads are important dimensions for evaluating performance. Microsphere suppliers in the bioreagent industry optimize polymerization processes and surface modifications to meet the needs of different platforms. For example, chemiluminescence immunoassays typically require carboxyl magnetic beads with high magnetic responsiveness and low sedimentation, while lateral flow platforms focus on the uniformity and release performance of colored or fluorescent microspheres.

The stability of signal amplification materials also affects detection results. For example, the activity of labels such as acridinium esters, alkaline phosphatase, or horseradish peroxidase can be affected by temperature, pH, and buffers. Manufacturers need to establish accelerated stability tests to evaluate performance changes under different transportation and storage conditions. In industry practice, raw materials are generally required to maintain key indicators within specified ranges throughout the labeled shelf life, but absolute guarantees are not recommended.

Industry Practices for Raw Material Selection and Validation

When selecting core raw materials, IVD reagent manufacturers typically follow a process of "performance validation — pilot trial production — scale-up — stability evaluation." First, the procurement department and R&D department jointly evaluate supplier qualifications, quality systems, and supply capacity. Second, the laboratory conducts functional testing, which may include sensitivity, linear range, precision, and accelerated stability. Finally, trial production confirms the compatibility between raw materials and processes. Since diagnostic reagents are regulated as medical devices, raw material changes may require re-design validation or registration changes, so preliminary evaluation should be as thorough as possible.

Attention should be paid to residual impurities in raw materials, such as nucleases, proteases, and endotoxins;

Suppliers should be required to provide batch quality inspection reports and documentation of key material sources;

Incoming inspection standards should be established for key raw materials, rather than relying solely on supplier data;

Correlation analysis between raw materials and finished product performance should be established to identify critical quality attributes.

Quality Control Documentation and Regulatory Support

When the bioreagent industry supplies raw materials to the IVD field, quality documentation and regulatory support are increasingly important. Suppliers need to provide certificates of analysis, material safety data sheets, stability reports, and change notifications. For raw materials of animal origin, source certification and virus inactivation information are also required.These documents are not only a component of downstream companies' quality system audits, but also help demonstrate the compliance of raw materials during registration submissions.

In document management, the traceability of batches and lot numbers is critical. Each batch of raw materials should be linked to specific production records, quality control data, and shipping records. In the event of deviations or complaints, it should be possible to quickly identify the affected batches and implement corrective and preventive actions. Through electronic quality management systems, companies can improve data integrity and query efficiency while reducing the risk of errors in manual records.

Future Trends: From Single Raw Materials to Total Solutions

As diagnostic technologies advance toward molecular POCT, multiplex detection, and automated pipelines, the bioreagent industry is extending from providing single raw materials to offering total solutions. For example, suppliers not only provide polymerases but also offer optimized buffer systems, positive quality controls, and lyophilization process recommendations. This model helps shorten downstream companies' R&D cycles, but it also places higher demands on suppliers' technical integration capabilities.

In addition, domestic diagnostic raw materials have accelerated their entry into the market after the pandemic. Although domestic bioreagents have achieved import substitution capability in some areas, differences remain across different projects, and companies need to conduct thorough validation based on specific application scenarios. From an industry trend perspective, standardization, traceability, and a stable supply chain will become key factors in future competition for diagnostic raw materials. Practitioners in the bioreagent industry should continuously monitor technological iterations and regulatory changes, and promote product upgrades in a rational and compliant manner.